EGFR and cancer: Very recently, Elbadawi reported 2-arylquinolines and 2,6-diarylquinoline derivatives as new dual EGFR/FAKIs to fight cancer by a non-overlapping downstream signalling/inhibition [62], as previously demonstrated by Ai [31].